AMLX

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today reported financial and business results for the first quarter ended March 31, 2026. With enrollment complete in the pivotal...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1...

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hol...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyxs senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates...

Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Mizuho increased their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an "outperform" rating in a research note on Tuesday...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of some unusual options trading activity on Monday. Traders bought 3,000 call options on the stock. This is an increase of...

Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week High - Time to Buy...

Amylyx Pharmaceuticals (NASDAQ:AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a...